The cytolytic function of NK cells can be initiated through a variety of processes, including de-granulation and stimulation of death receptors, and is essential in the normal physiology for the removal of diseased and dysfunctional cells. Second, NK cells can produce a variety of inflammatory cytokines in response to receptor stimulation and inflammatory cytokine-induced activation. These effector functions of NK cells are essential components of the immune response and are the main mechanisms by which NK cells provide function as part of the immune system.
NK cells are interesting candidates for immunotherapy due to their innate and independent cell killing capability, their suitability for collection, expansion and storage, and the ability to direct them towards specific target cells. The use of allogeneic NK cells can provide an additional functional immune capacity in a patient, and this can be especially effective in pathologies that are compromising the host immune system. In addition, NK therapy has a lower risk of engendering new stimulation or over-stimulation of host immune mechanisms which are an unfortunate side-effect of several current cellular immunotherapy methods.
The MedXCell Group is developing new therapeutic products based on formulations containing allogeneic human NK cells. These products will take advantage of natural ability of NK calls to act as cytotoxic agents as well as the ability of monoclonal antibodies and other ligands to direct the NK cell cytotoxicity to populations of cells responsible for pathology. Envisaged indications include oncology, autoimmunity and infectious disease.
The MedXCell Group expects to be able to establish rapidly a platform to underpin the development of products for multiple indications using a single population of NK cells. This population of cells will not undergo modification and will be passively armed using indication-specific ligands to recognize target cells.
In this way, the MedXCell Group platform will serve as a “toolkit” for the rapid formulation and validation of new cell targets for immunotherapy.
For more information, please contact: